NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

CompletedPhase 1

Sponsor: Pfizer

Conditions: Rheumatoid Arthritis

Interventions: SBI-087

Countries: United States, Canada

The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit.
* Must meet criteria for rheumatoid arthritis with functional class I to III.
* Diagnosis of rheumatoid arthritis more than 6 months before study day 1 and rheumatoid arthritis onset after 16 years of age

Exclusion Criteria:

* Any significant health problems other than rheumatoid arthritis.
* Treatment of greater than 10 mg of prednisone per day.
* Treatment with cyclophosphamide.

Locations (6)

Miami, Florida, United States
Durham, North Carolina, United States
Dallas, Texas, United States
Edmonton, Alberta, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada